The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia
The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complication...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU UK |
| Publicado: |
Interdisciplinary Academy of Pain Medicine
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7fad54fdfbf54f1ca15f44a7e80513d8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7fad54fdfbf54f1ca15f44a7e80513d8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7fad54fdfbf54f1ca15f44a7e80513d82021-11-24T01:29:57ZThe effectiveness of moxifloxacin in the treatment of community-acquired pneumonia10.31636/prmd.v4i2.12616-339X2617-2925https://doaj.org/article/7fad54fdfbf54f1ca15f44a7e80513d82021-11-01T00:00:00Zhttps://perioperative.org.ua/index.php/prtmdc/article/view/78https://doaj.org/toc/2616-339Xhttps://doaj.org/toc/2617-2925 The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent. Dmytro DmytriievOleksandr NazarchukYuliana BabinaInterdisciplinary Academy of Pain MedicinearticlefluoroquinolonesmoxifloxacintreatmentpneumoniaCOVID-19MedicineRRUUKPerioperative Medicine, Vol 4, Iss 2 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU UK |
| topic |
fluoroquinolones moxifloxacin treatment pneumonia COVID-19 Medicine R |
| spellingShingle |
fluoroquinolones moxifloxacin treatment pneumonia COVID-19 Medicine R Dmytro Dmytriiev Oleksandr Nazarchuk Yuliana Babina The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| description |
The article presents the results of domestic and international studies of the use of the fourth-generation fluoroquinolone moxifloxacin in the treatment of commu-nity-acquired pneumonia and pneumonia caused by SARS-CoV-2. Analysis of the clinical use of moxifloxacin in the treatment of complications of the respiratory tract infec-tions indicates its high efficiency and bioavailability, a low risk of resistance, which makes it possible to recommend it for widespread use in the work of a practicing doctor. Ge-neric drug Maxicin (Yuria-Pharm), available as a 20 mg/ml concentrate in a 20 ml vial, can significantly reduce the cost of treatment and optimize infusion therapy by choosing both volume and solvent.
|
| format |
article |
| author |
Dmytro Dmytriiev Oleksandr Nazarchuk Yuliana Babina |
| author_facet |
Dmytro Dmytriiev Oleksandr Nazarchuk Yuliana Babina |
| author_sort |
Dmytro Dmytriiev |
| title |
The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_short |
The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_full |
The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_fullStr |
The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_full_unstemmed |
The effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| title_sort |
effectiveness of moxifloxacin in the treatment of community-acquired pneumonia |
| publisher |
Interdisciplinary Academy of Pain Medicine |
| publishDate |
2021 |
| url |
https://doaj.org/article/7fad54fdfbf54f1ca15f44a7e80513d8 |
| work_keys_str_mv |
AT dmytrodmytriiev theeffectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT oleksandrnazarchuk theeffectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT yulianababina theeffectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT dmytrodmytriiev effectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT oleksandrnazarchuk effectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia AT yulianababina effectivenessofmoxifloxacininthetreatmentofcommunityacquiredpneumonia |
| _version_ |
1718416043669454848 |